NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Generate Biomedicines, Inc. (GENB) Stock Analysis

Generate Biomedicines, Inc. (GENB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

GENB

$16.39

+$0.05 (+0.31%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GENB with… →

GENB Key Statistics

As of Sep 4, 2026
Trading
Open
$16.39
Previous Close
$16.34
Day's Range
15.98–16.62
52-Week Range
11.00–22.67
Volume
724.70K
Valuation
Market Cap
$2.10B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
79.44
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.10
Financials (FY)
Revenue (FY)
$31.89M+55.89%
Net Income (FY)
−$203.15M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
128.35M
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
997.44K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GENB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$31.89M−$203.15M−637.0%
2024$20.46M−$173.77M−849.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$31.89M—−$235.07M−$203.15M−637.0%
2024$20.46M—−$196.94M−$173.77M−849.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GENB Valuation vs Biotechnology Median

Median of 656 stocks
MetricGENBBiotechnology medianvs median
P/S ratio79.4415.265.2x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Generate Biomedicines, Inc. (GENB) carries a market capitalisation of $2.10B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 312.

Over the past 52 weeks the price has ranged from $11.00 to $22.67. The most recent close on file for GENB is $16.39, dated September 4, 2026. That is +$0.05 (+0.31%) against the previous close. The latest close sits 49% above that 52-week low.

Financial Health

In fiscal 2025, Generate Biomedicines, Inc. reported revenue of $31.89M. That is +55.89% against the prior fiscal year, when revenue was $20.46M. The same year closed with a net loss of $203.15M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −2.1.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 79.44 times revenue. On price-to-sales that is 5.2 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The stored price history starts on February 27, 2026, and the total return since then is +29.57%.

Growth & Income

The record shows no dividend for GENB.

2026 is still running; the price is +29.57% year to date.

Peer Comparison

Generate Biomedicines, Inc. (GENB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Generate Biomedicines, Inc. GENB $2.10B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Generate Biomedicines, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Generate Biomedicines, Inc.

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.

Visit website →